Deleterious effect of proton pump inhibitors on the disease course of cirrhosis

Tamás Janka(University of Debrecen), Zsuzsanna Vitális(Semmelweis University), Tamás Tornai(University of Debrecen), Mária Papp(University of Debrecen), I Altorjay, Brigitta Borbély(University of Debrecen), Dávid Tornai(Beth Israel Deaconess Medical Center)
European Journal of Gastroenterology & Hepatology
August 29, 2019
10.1097/meg.0000000000001499
Cited by 37

Related Papers

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
|The Lancet|2022|295
MicroRNA 122, Regulated by GRLH2, Protects Livers of Mice and Patients From Ethanol-Induced Liver Disease
|Gastroenterology|2017|157
Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis
|Journal of Hepatology|2022|140
IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis
|Hepatology|2022|103
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
|˜The œLancet. Gastroenterology & hepatology|2021|96